IMM vs. SBTX, COS, C4XD, DDDD, FUM, TRX, OKYO, AOR, SAR, and POLB
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), Tissue Regenix Group (TRX), OKYO Pharma (OKYO), AorTech International (AOR), Sareum (SAR), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
ImmuPharma (LON:IMM) and SkinBioTherapeutics (LON:SBTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.
17.4% of ImmuPharma shares are owned by institutional investors. Comparatively, 16.6% of SkinBioTherapeutics shares are owned by institutional investors. 48.3% of ImmuPharma shares are owned by insiders. Comparatively, 20.4% of SkinBioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ImmuPharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, SkinBioTherapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.
In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled SkinBioTherapeutics'average media sentiment score.
ImmuPharma has higher earnings, but lower revenue than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
ImmuPharma has a net margin of 3,519.56% compared to SkinBioTherapeutics' net margin of -237.95%. SkinBioTherapeutics' return on equity of -115.86% beat ImmuPharma's return on equity.
Summary
ImmuPharma beats SkinBioTherapeutics on 7 of the 11 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 7/2/2025 by MarketBeat.com Staff
